Clinical trials: Rectal Tumours
Colorectal Cancer
The Investigation of the EtCO₂- PaCO₂ Relation During Laparoscopic Colon Surgery
Et-C02 is used to predict PaCO2 during surgery. There are controversies regarding the value of ETCO2 to predict PaCO2. The aim of this study was to investigate the relation between Et-CO₂ and PaCO₂ measurements in patients…
- Trial name
- NCT01707511
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Diskapi Teaching and Research Hospital
Locally Advanced Rectal Cancer (LARC)
AI-Based Prediction of Pathological Response in Rectal Cancer Patients Receiving Total Neoadjuvant Therapy
This study aims to better understand how body composition, inflammation, and nutrition affect how rectal cancer responds to treatment.
- Trial name
- CINR-AI (NCT07049627)
- Testing
- Total Neoadjuvant Therapy (TNT)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 93 people
- Sponsor
- Ankara Etlik City Hospital
Rectal Cancer, Oncology
Outcomes of Neoadjuvant Therapy for Rectal Cancer in a Tertiary Asian Institute
This is a retrospective cohort study that aims to evaluate the correlation of magnetic resonance tumour regression grade (mrTRG) and pathological TRG (pTRG) of locally advanced rectal cancer after neoadjuvant long course…
- Trial name
- NCT05607186
- Testing
- neoadjuvant long course chemoradiotherapy
- Volunteers
- 59 people
- Sponsor
- Singapore General Hospital
Breast Carcinoma, Cervical Carcinoma
The Ohio State University (OSU) SCREEN Community Program
This clinical trial develops and tests how well a multi-level intervention (MLI), The Ohio State University (OSU) SCREEN Community Program, works to increase screening and follow-up for breast, cervical and colorectal (CRC)…
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
- Trial name
- NCT06666192
- Testing
- Cancer Screening, Discussion, Educational Activity
- Where
- United States
- Volunteers
- 2,067 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Radiation-induced Diarrhoea in Prostate and Rectal Cancer
Radiation-induced Diarrhoea During Curative EBRT of Prostate and Rectal Cancer
Approx. 80% of patients with prostate and rectal cancer who receive radiation therapy (RT) experience acute radiation-induced diarrhea (RID).
- Trial name
- PRECANU (NCT05684432)
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Aalborg University Hospital
Colorectal Cancer, Diarrhea
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Colorectal Cancer, Diarrhea, Neutropenia
- Trial name
- NCT01164215
- Testing
- fluorouracil, leucovorin, oxaliplatin
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colon Rectal Cancer, Surgical Site Infection
Surveillance and Implementation of a Bundle of Care to Reduce Surgical Site Infection in Colorectal Surgery (CCR-VINCat)
The Nosocomial Infection Surveillance Program in Catalonia (VINCat) monitors surgical site infection (SSI) in elective colorectal surgery since 2007 in 55 public and private acute care hospitals.
- Trial name
- CCR-VINCat (NCT04496635)
- Testing
- Implementation of a bundle of care
- Where
- Spain
- Volunteers
- 60,000 people
- Sponsor
- Hospital de Granollers
Colorectal Neoplasms
Evaluation of Some Risk Factors Associated With Colorectal Cancer
1. Evaluation of some risk factors (e.g. smoking, heavy metal exposure, and organophosphorus exposure) on CRC. 2. Estimation of KRAS and BRAF genes mutations associated with CRC. 3.
- Trial name
- NCT05170360
- Testing
- Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:
- Volunteers
- 100 people
- Sponsor
- Assiut University
Rectal Cancer
ArtiSential® for Rectal Cancer Surgery
This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic low or ultralow anterior resection for…
- Trial name
- NCT06236282
- Testing
- ArtiSential®
- Where
- South Korea
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Colorectal Cancer, Neoplasm of Uncertain Malignant Potential
Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer
RATIONALE: Diagnostic imaging procedures, such as fludeoxyglucose F 18 PET, may be effective in detecting cancer or recurrence of cancer, or premalignant polyps.
- Trial name
- NCT00550628
- Testing
- DNA methylation analysis, fluorescence in situ hybridization, gene expression analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Neoplasm, Hereditary Nonpolyposis
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
This is a randomized, placebo-controlled Phase I/II multi-center trial, of the safety and efficacy of Celecoxib in a cohort of 81 HNPCC subjects and gene carriers.
- Trial name
- NCT00001693
- Testing
- Celecoxib (SC-58635)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer (CRC)
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Colorectal Cancer (CRC)
- Trial name
- NCT07106892
- Testing
- HLX43 Dose 1;, HLX43 Dose 2;, HLX43 Dose 3;
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Colorectal Neoplasms, Anastomotic Leak
Anastomotic Leakage and Enhanced Recovery Pathways After Colorectal Surgery
Prospective observational multicenter study on the influence of adherence to enhanced recovery pathways on early outcomes (anastomotic leakage, morbidity, mortality, readmission, reoperation rates and length of postoperative…
- Conditions
- Colorectal Neoplasms, Anastomotic Leak, Surgery--Complications
- Trial name
- iCral2 (NCT03771456)
- Testing
- Colorectal resections
- Where
- 41 sites in Italy
- Volunteers
- 1,748 people
- Sponsor
- Ospedale C & G Mazzoni
Anastomotic Leakage in Colon Surgery, Anastomotic Leak Rectum
Anastomotic Leakage in Colorectal Cancer Surgery in Syria
Anastomotic leakage is a serious complication of colorectal cancer surgery, particularly in resource-limited and conflict-affected settings.
- Conditions
- Anastomotic Leakage in Colon Surgery, Anastomotic Leak Rectum, Anastomotic Leak Large Intestine
- Trial name
- NCT07092631
- Where
- Syria
- Volunteers
- 119 people
- Sponsor
- Elie Bitar
Gastric Cancer, Colo-rectal Cancer
Association Between ABO Polymorphism and Gastric/Colorectal Cancers
To assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/or colorectal cancers relative to healthy controls by real time PCR.
- Trial name
- NCT06149923
- Testing
- quantitative Real-time PCR
- Volunteers
- 184 people
- Sponsor
- Assiut University
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Colorectal Neoplasms
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
After consultation with the Korean Health Authorities, the two Post-Authorization Safety Studies EMR 62202-509 (NCT01082315) and EMR 62241-508 (NCT01075828) were combined within one study protocol EMR 062202-551.
- Trial name
- NCT01082315
- Testing
- Erbitux (Cetuximab)
- Where
- South Korea
- Volunteers
- 730 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Neoplasms, Peritoneal Neoplasms
PIPAC for Peritoneal Metastases of Colorectal Cancer
This is multicentre, open-label, single-arm phase II study that investigates the feasibility, safety, tolerability, preliminary efficacy, costs, and pharmacokinetics or repetitive electrostatic pressurised intraperitoneal aerosol…
- Conditions
- Colorectal Neoplasms, Peritoneal Neoplasms, Appendiceal Neoplasms, Peritoneal Carcinomatosis
- Trial name
- CRC-PIPAC (NCT03246321)
- Testing
- repetitive ePIPAC-OX
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Koen Rovers
Colorectal Cancer
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either…
- Trial name
- NCT00097578
- Where
- United States
- Volunteers
- 1,953 people
- Sponsor
- Genentech, Inc.
Rectal Cancer
ELRR by TEM Versus Laparoscopic TME in iT2N0M0 SMALL LOW RECTAL CANCER
The present prospective randomized study investigated the results of ELRR (ENDOLUMINAL LOCO-REGIONAL RESECTION BY TRANSANAL ENDOSCOPIC MICROSURGERY) versus LTME (LAPAROSCOPIC TOTAL MESORECTAL EXCISION) in the management of 100…
- Trial name
- ELRRvsLTME (NCT01609504)
- Testing
- ELRR BY TEM, LTME
- Volunteers
- 283 people
- Sponsor
- University of Roma La Sapienza